HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Nephrology2440 papers

Obstructive nephropathy

Last edited: 4/23/2026

Overview

Obstructive nephropathy, often secondary to benign prostatic hyperplasia (BPH), involves obstruction of the urinary tract leading to impaired kidney function and potential renal damage. 2 3 6

Diagnosis

Clinical assessment focusing on lower urinary tract symptoms (LUTS) such as urinary hesitancy, weak stream, and nocturia.

Uroflowmetry to measure urine flow rates.

Post-void residual (PVR) measurement to assess retained urine volume.

Renal function tests (serum creatinine, estimated glomerular filtration rate [eGFR]) to evaluate kidney damage. 6 24

Management

First-line treatments:

- α1-adrenergic receptor antagonists (α1-blockers): Tamsulosin, alfuzosin (doses vary by agent). - 5α-reductase inhibitors: Finasteride, dutasteride (typically 5 mg/day and 0.5 mg/day, respectively).

Minimally invasive surgical therapies (MISTs):

- Transurethral resection of the prostate (TURP). - Laser procedures (e.g., holmium laser enucleation of the prostate [HoLEP], diode laser enucleation). - Prostatic urethral lift (UroLift). - Robotic waterjet ablation (Aquablation). 7 10 22 30 34

Special Populations

Elderly: Consider comorbidities and surgical risks; α1-blockers and MISTs are often preferred over traditional TURP. 6 24

Comorbidities: Patients with metabolic syndrome may require tailored management considering cardiovascular risks associated with certain treatments like 5α-reductase inhibitors. 5 18

Key Recommendations

Initiate management with medical therapy, including α1-blockers or 5α-reductase inhibitors, for symptom relief and to delay progression in mild to moderate BPH. (Evidence: Moderate) 2 3 6

Consider minimally invasive surgical therapies for patients with severe symptoms or complications unresponsive to medical therapy. (Evidence: Moderate) 7 10 22 30

Regularly monitor renal function through eGFR and PVR in patients with obstructive nephropathy to assess for progression of kidney damage. (Evidence: Moderate) 6 24

References

Showing 100 most recent of 1072 indexed papers.

1 Wang Y, Chen Z, Huang K, Zhang X, Chen C, Xu Y. Comparison of the BOPPPS model combined with rain classroom teaching and traditional method on nephrology education for fifth-year undergraduates. BMC medical education 2026. link 2 Zhang X, Liang T, Dong Y, Gao H. Minimally invasive treatments for benign prostatic hyperplasia: A narrative review. Medicine 2026. link 3 Bevilacqua G, Carino D, Salciccia S, Gentilucci A, Forte F, Marco MD et al.. Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study. The Prostate 2026. link 4 Bettencourt A, Wu J, Borrell JA, Furtado TP, Mills JN, Jayadevan R et al.. Ejaculatory function after robotic waterjet ablation for the treatment of benign prostatic hyperplasia: a systematic review. International journal of impotence research 2026. link 5 Gao W, Guo Y, Yu X, Zhang T, Gong H, Zhang Y. The Association Between Metabolic Syndrome and Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. American journal of men's health 2026. link 6 Edmonds V, Galen E, Mbassa R, Meeks W, Forbes CM, Bhojani N et al.. Surgical Management of Benign Prostatic Hyperplasia: Analysis of Patient and Provider Factors Associated with Surgical Management Using the American Urological Association Quality Registry Dataset. Urology 2026. link 7 Pace KJC, Li T, Elterman DS. Next-gen minimally invasive surgical therapies for benign prostatic hyperplasia: innovations, selection, and best practices- a review from European Association of Urology endourology. Current opinion in urology 2026. link 8 Scherrer M, Brunaiova L, Furrer M, John H, Schwartz J, Lucca I et al.. How safe is teaching radical cystectomy? : Results from the prospective Swiss society of urology database. World journal of urology 2026. link 9 Aydın ME, Aykaç A, Kaya C, Sungur M. Comparative analysis of EAU, AUA, and NCCN guidelines for the management of non-muscle invasive bladder cancer. BMC urology 2026. link 10 Mari A, Cindolo L, Fiori C, Lambertini L, Secco S, Russo GI et al.. Trends for ejaculatory sparing and minimally invasive surgical treatments adoption for lower urinary tract symptoms related to BPH in Italy: screenshot from the Italian society of urology (SIU) benign research network. Minerva urology and nephrology 2026. link 11 Abdulmajeed A, Bekiroglu F, Aydin A, Laguna P, Zeng G, Pavlov V et al.. Guidelines adherence in non-muscle-invasive bladder cancer: a global survey of 3595 participants. BJU international 2026. link 12 Saouli A, Contieri R, Quhal F, Hurle R, Guenouni M, Ploussard G et al.. Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group. Actas urologicas espanolas 2026. link 13 Zhang C, Huang S, Jiang F, Pu X. Implementation of problem-based learning pedagogy with integration of tamsulosin management in traditional urology residency training under the multidisciplinary team model. Pakistan journal of pharmaceutical sciences 2026. link 14 Diana P, Gallioli A, Uleri A, Mas L, Pujol R, Territo A et al.. Attendings versus supervised residents: Educational results and future perspective in transurethral resection of bladder tumors. Actas urologicas espanolas 2026. link 15 Zhao Z, Wu C, Xiong Y, Wang W, Qin F, Yuan J. Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS). The aging male : the official journal of the International Society for the Study of the Aging Male 2026. link 16 Gokhale P, Zapata LV. Immune-Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis. Cancer medicine 2026. link 17 Lin J, Fu W, Huang J, Liu M, Cai H. Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data. World journal of urology 2026. link 18 Tu H, Ju C, McGurnaghan SJ, Blackbourn LAK, Pearson E, Wei L et al.. Cardiovascular safety of 5α-reductase inhibitors in people with benign prostatic hyperplasia and type 2 diabetes: a propensity score-matched analysis. European heart journal. Cardiovascular pharmacotherapy 2026. link 19 Münker KA, Reineke D, Schneidewind L, Müssgens C. A Rare Case of a Plasmacytoid and Sarcomatoid Differentiated Urothelial Bladder Carcinoma with a Single Metastasis to the Right Ventricle of the Heart and Rapid Review of Single Heart Metastasis in Bladder Cancer. Urologia internationalis 2026. link 20 Hirao K, Sano T, Taniguchi H, Yanishi M, Muguruma K, Kinoshita H. Risk factors and management of hypotension and nausea during 5-aminolevulinic acid-assisted transurethral resection of bladder tumors under spinal anesthesia. Photodiagnosis and photodynamic therapy 2026. link 21 Gunturi A, Ceraolo C, Kolady R, Dogra N, Cheng G, Hines L et al.. The Impact of Anesthesia-induced Intraoperative Hypotension on Hemostasis During Holmium Laser Enucleation of the Prostate. Urology 2026. link 22 Katsumata Y, Yamamoto S, Iwata H, Kuroiwa H, Fukuhara H, Fukata S et al.. Agent-specific differences in sustained intraoperative hypotension during oral 5-Aminolevulinic acid-guided transurethral resection of bladder tumor: A retrospective observational study. Photodiagnosis and photodynamic therapy 2026. link 23 Shen J, Zhao Z, Li Z, Wang R. Bladder cancer-induced CVD mortality: Role of CAPG protein. PloS one 2026. link 24 Anract J, Klein C, Sarrazin C, Pinar U, Chevrot A, Fassi-Fehri H et al.. Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH). The French journal of urology 2025. link 25 van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Compérat E, Dimitropoulos K et al.. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines. European urology 2025. link 26 Nedbal C, Gauhar V, Herrmann T, Singh A, Talyshinskii A, Al Jaafari F et al.. Simulation-based training in minimally invasive surgical therapies (MIST): current evidence and future directions for artificial intelligence integration-a systematic review by EAU endourology. World journal of urology 2025. link 27 Corsini C, Robesti D, Villa L, Montorsi F, Pietropaolo A, Panthier F et al.. Is Pulse Modulation the Future of Laser Technology in Endourology: Evidence from a Literature Review - Section of EAU Endourology. European urology focus 2025. link 28 Altieri VM, Di Bello F, Saldutto P, Rocca R, Romani ML, Vena W et al.. Outcomes and safety of trans perineal laser ablation of the prostate: a systematic review. World journal of urology 2025. link 29 Busetto GM, Lombardo R, De Nunzio C, Santoro G, Tocci E, Schiavone N et al.. Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH. Prostate cancer and prostatic diseases 2025. link 30 Akgul B, Tozsin A, Aydın A, Tokas T, Romero-Otero J, Ortner G et al.. Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement. World journal of urology 2025. link 31 Eliwa A, Aldarraji A, Abdelwahab K, Salem E. Randomized prospective trial comparing ejaculatory preservation HoLEP versus standard HoLEP: the other face of the coin. World journal of urology 2025. link 32 Clout M, Lewis AL, Cochrane M, Young GJ, Abrams P, Blair PS et al.. Five-year Follow-up of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods-A Noninferiority Randomised Controlled Trial of Urodynamics. European urology focus 2025. link 33 Moretto S, Wirtzfeld N, Doizi S. Local anesthesia for UroLift. World journal of urology 2025. link 34 Lin D, Luo C, Cui K, Xu H, Yuan H, Luan Y et al.. 1470 nm diode laser enucleation versus bipolar transurethral resection of the prostate for the surgical management of benign prostatic hyperplasia: a randomized comparison. Lasers in medical science 2025. link 35 Ceraolo CA, Winzer BM, Fairbourn JD, Phan D, Jain RK, Quarrier SO. "Defining the Drip: A Systematic Review of Incontinence Definitions and Predictors Following HoLEP". Current urology reports 2025. link 36 Bakr AM, El-Sakka AI. Effects of alpha-1 adrenergic receptor blockers on erectile function: a systematic review. Expert opinion on pharmacotherapy 2025. link 37 Copelan O, Moss J, Freedman S, Coutinho K, Elterman D, Marotte J et al.. Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. The journal of sexual medicine 2025. link 38 Du R, Wang P, Gao Z, Liu H, Sun Z, Gu L et al.. Comparative study of low-power versus high-power holmium laser enucleation of the prostate for large volume benign prostatic hyperplasia. Lasers in medical science 2025. link 39 Baboudjian M, De Nunzio C, Cornu JN. Current Guidelines for the Management of Benign Prostatic Obstruction: Practical Tips for Patient Selection to Achieve Optimal Outcomes. European urology focus 2025. link 40 Sheba M, El Gamal F, Abd El Wahed M, Kotb S, Meshref A, Aly Hussein H et al.. Randomised controlled trial comparing safety and efficacy of Urolift to monopolar TURP. Urologia 2025. link 41 Porto JG, Bhatia AM, Bhat A, Suarez Arbelaez MC, Blachman-Braun R, Shah K et al.. Transurethral resection of the prostate across continents: a meta-analysis evaluating quality of gold standard in the twenty-first century. World journal of urology 2025. link 42 Lambertini L, Sandulli A, Coco S, Paganelli D, Cadenar A, Dell'Oglio P et al.. Complication rate across the minimally invasive surgical treatments (MISTs): where do we stand? A systematic review of the literature. Prostate cancer and prostatic diseases 2025. link 43 Schwartzmann I, Chughtai B. Practical Approaches to Evaluating Patients with Benign Prostatic Hyperlasia Using Home-based Tools and Apps. European urology focus 2025. link 44 Malmström PU, Wang EYH. Paradigm shift in the treatment of bladder cancer? The Swedish perspective. Scandinavian journal of urology 2025. link 45 Wong R, Matulewicz RS, Bjurlin MA. A Urologist's Guide to Managing Bladder Cancer in Patients Who Smoke. European urology focus 2025. link 46 Uleri A, Fourmarier M, Long-Depaquit T, Baboudjian M. Do We Need Referral Centers for Benign Prostatic Hyperplasia that Offer More Options with Expertise? Con. European urology focus 2025. link 47 Pesce F, Cheungpasitporn W. Vibe Coding in nephrology education: clinician-led, AI-assisted development of open-source interactive learning tools. Renal failure 2025. link 48 Keenan RA. Roadmap for the transition to robotic radial cystectomy for patients with bladder cancer in a tertiary urology unit: planning for change. BMJ leader 2025. link 49 Kim IE, Allu S, Whittelsey M, Kent V, Onal EG, Nguyen C et al.. Student Urology Conference Increases Participant Knowledge of Urology Match and Confidence in Research. Urology 2025. link 50 Khorsandi N, Porten S, VandenBussche CJ, Greenland N, Vohra P. Bridging Perspectives: Integrating urologist and cytopathologist insights of urine cytology. Seminars in diagnostic pathology 2025. link 51 Farré A, Huguet J, Basile G, Diéguez L, Izquierdo P, Sánchez R et al.. Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy. Actas urologicas espanolas 2025. link 52 Liedberg F, Mariappan P, Gontero P. Clinical Implementation of Urinary Biomarkers for Surveillance of Non-muscle-invasive Bladder Cancer (NMIBC): Considerations from the European Association of Urology NMIBC Guideline Panel. European urology oncology 2025. link 53 Digiacomo A, Orsini A, Cicchetti R, Spadano L, De Santis S, Di Sessa L et al.. Chatgpt vs traditional pedagogy: a comparative study in urological learning. World journal of urology 2025. link 54 Ramanujan S, Orji P, Chiu A, Kumar SS, Jevnikar W, Cox B et al.. Benign Prostatic Hyperplasia Knowledge Deficits Among Male Urology Patients. Urology 2025. link 55 Wang B, Nandwana D, Helstrom E, Davis LE, Mishra K, Campbell R et al.. Beyond Citations: Exploring Gender and Racial Gaps in Urology Publications Through Citation and Altmetric Analysis. Urology 2025. link 56 Ryan PC, Sugrue DD, O'Connell C, Salloum A, Lynch TH, Smyth L et al.. Improving the quality of transurethral resection of bladder tumour (TURBT) operative notes following the European Association of Urology guidelines. Irish journal of medical science 2025. link 57 Cimadamore A, Moschini M, Teoh J, Albisinni S, Adwin Z, Shen Ta W et al.. Real-life perception of pathology reports in urology. Actas urologicas espanolas 2025. link 58 Nedbal C, Tramanzoli P, Somani BK, De Stefano V, Stramucci S, Pirola GM et al.. Current utility of artificial intelligence in benign prostate surgery: a review of literature on behalf of the EAU section of endourology. World journal of urology 2025. link 59 Soria F, Mari A, Moschini M, Naspro R, Hurle R, Miglioranza E et al.. The current role of photodynamic diagnosis (PDD) in the management of non-muscle invasive bladder cancer: the Italian Society of Urology (SIU) Position Paper. Minerva urology and nephrology 2025. link 60 Mertens LS, Bruins HM, Contieri R, Babjuk M, Rai BP, Puig AC et al.. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels. European urology oncology 2025. link 61 Bekiroglu F, Abdulmajeed A, Aydin A, Laguna P, Zeng G, Pavlov V et al.. The worldwide adoption of enhanced endoscopic imaging in diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC): snapshot analysis from a global survey. World journal of urology 2025. link 62 Yong C. Educating the Educator: Understanding Essential Components of Contemporary Urology Residency Training. Current urology reports 2025. link 63 Hsieh TY, Hong JH, Chueh JS. Comparing the clinical outcomes and learning curves of prostatic urethral lift performed by experienced versus naïve urologists. World journal of urology 2025. link 64 Abou Chakra M, Packiam VT, McElree IM, Mott SL, O'Donnell MA. The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer. Urologic oncology 2025. link 65 MacDonald L, Smith M, Bree KK. New Paradigms for Bladder Cancer Management in Geriatrics. Clinics in geriatric medicine 2025. link 66 Wang B, Bao EH, Jiang BL, Yang L, Liu Y, Xia L et al.. Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database. Expert opinion on drug safety 2025. link 67 Zhang Z, Lv L, Jiang F, Guan S, He D, Song H et al.. Real-world safety assessment of tamsulosin based on adverse event analysis from the FAERS database. Scientific reports 2025. link 68 Gupta AK, Bamimore MA, Williams G, Talukder M. Finasteride Use: Evaluation of Depression and Suicide Risk. Journal of cosmetic dermatology 2025. link 69 Chen HY, Zhao H, Yang JJ, Zhang Q, Yan MM, Qiu XY. Reassessment of pioglitazone and bladder cancer based on FAERS database. Expert opinion on drug safety 2025. link 70 Liu X, Wang Z, Peng C, Zhou J, Chen M, Luo L et al.. Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system. Expert opinion on drug safety 2025. link 71 Nakagawa Y, Yamamoto C, Kawajiri H, Watanabe M, Yamada T, Yamada Y et al.. Whole Genome Sequencing of Clinical . International journal of molecular sciences 2025. link 72 Ahmed ME, Andrews JR, Mahmoud AM, Reitano G, Thapa P, Tyson MD et al.. Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes. The Journal of urology 2025. link 73 Fosbøl EL, Stahl A, Røder A, Nordsten CB, Østergaard L, Sehested TSG et al.. Transurethral resection of the prostate (TUR-P) and associated risk of infective endocarditis. Infection 2025. link 74 Yonezaki S, Shimizu MS, Ota T, Ozasa S, Akabame S, Ide S et al.. Multiple arterial aneurysms in a patient with spondylitis following intravesical Bacillus Calmette-Guérin administration for bladder cancer: A case report. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2025. link 75 Tania C, Sihombing AT, Siregar S. Comparison of direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for venous thromboprophylaxis after radical cystectomy: A systematic review and meta-analysis. Urologic oncology 2025. link 76 Jeong JY, Kim MK, Shin JY. The association between alphablockers in the treatment of benign prostatic hyperplasia and heart failure: A nationwide population-based cohort study in South Korea. International journal of clinical pharmacology and therapeutics 2025. link 77 Salem J, Becher KF, Bschleipfer T, Dreikorn K, Höfner K, Madersbacher S et al.. [Minimally invasive treatment of benign prostatic hyperplasia : The German S2e guideline 2023-part 4]. Urologie (Heidelberg, Germany) 2024. link 78 Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC et al.. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. The Journal of urology 2024. link 79 Gontero P, Birtle A, Capoun O, Compérat E, Dominguez-Escrig JL, Liedberg F et al.. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. European urology 2024. link 80 Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC et al.. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). The Journal of urology 2024. link 81 Devlies W, de Jong JJ, Hofmann F, Bruins HM, Zuiverloon TCM, Smith EJ et al.. The Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults Presenting with Haematuria: A Systematic Review from the European Association of Urology Guidelines Office. European urology focus 2024. link 82 Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK et al.. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network : JNCCN 2024. link 83 Yoosuf BT, Panda AK, Kt MF, Bharti SK, Devana SK, Bansal D. Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Scientific reports 2024. link 84 Fu X, Wang Y, Lu Y, Liu J, Li H. Association between metabolic syndrome and benign prostatic hyperplasia: The underlying molecular connection. Life sciences 2024. link 85 Porto JG, Bhatia AM, Bhat A, Suarez Arbelaez MC, Blachman-Braun R, Shah K et al.. Evaluating transurethral resection of the prostate over twenty years: a systematic review and meta-analysis of randomized clinical trials. World journal of urology 2024. link 86 Shin BNH, Qu L, Rhee H, Chung E. Systematic review and network meta-analysis of re-intervention rates of new surgical interventions for benign prostatic hyperplasia. BJU international 2024. link 87 Chen YY, Hua WX, Huang YH, Shen XY, You JN, Ding X. The safety and efficacy of five surgical treatments in prostate enucleation: a network meta-analysis. BMC urology 2024. link 88 Tawfik A, Abo-Elenen M, Gaber M, El-Abd A, Zoeir A, Saad S et al.. Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes. World journal of urology 2024. link 89 Hagovska M, Svihra J, Macko L, Breza J, Svihra J, Luptak J et al.. The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder. World journal of urology 2024. link 90 Samir M, Elaal AAA, Gad KAS, Basyony MW. Two-year follow-up comparing Rezūm therapy versus bipolar transurethral resection of the prostate for treating benign prostatic hyperplasia. A prospective randomized study. International journal of urology : official journal of the Japanese Urological Association 2024. link 91 Elshal AM, Ghazy M, Ghobrial FK. Enhancing continence post holmium laser enucleation of the prostate: assessment of novel technique through randomized clinical trial. Minerva urology and nephrology 2024. link 92 Morozov A, Bogatova S, Bezrukov E, Singla N, Teoh JY, Spivak L et al.. A systematic review of robot-assisted simple prostatectomy outcomes by prostate volume. World journal of urology 2024. link 93 Titus RS, Bhatia A, Porto JG, Shah K, Lopategui DM, Herrmann TRW et al.. Open simple prostatectomy in the last three decades: results of a meta-analysis. World journal of urology 2024. link 94 Zou P, Liu C, Zhang Y, Wei C, Liu X, Xu S et al.. Transurethral surgical treatment for benign prostatic hyperplasia with detrusor underactivity: a systematic review and meta-analysis. Systematic reviews 2024. link 95 Çakıroğlu B. Minimally invasive connective water vapor energy method for benign prostatic hyperplasia. Urologia 2024. link 96 Anezaki H, Endo F, Swan G, Takashima K, Rojanasarot S. Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan's public healthcare system. Journal of medical economics 2024. link 97 Kallidonis P, Spinos T, Peteinaris A, Somani B, Liatsikos E. Salvage holmium laser enucleation of the prostate after previous interventions: a systematic review. BJU international 2024. link 98 Cha JD, Galindo GFC, Denser CV, Silva CHAD, Carneiro A. Tranexamic acid for reducing blood loss in bipolar transurethral resection of the prostate: a systematic review of literature. Einstein (Sao Paulo, Brazil) 2024. link 99 Uleri A, Nicolas Cornu J, Gobbo A, Herrmann TRW, De Nunzio C, Hashim H et al.. Association of 5α-Reductase Inhibitors with Depression and Suicide: A Mini Systematic Review and Meta-analysis. European urology focus 2024. link 100 Shah SS, Zangla E, Qader MA, Chaturvedi S, Mannemuddhu SS. Embracing the (r)evolution of social media and digital scholarship in pediatric nephrology education. Pediatric nephrology (Berlin, Germany) 2024. link

Original source

[1]
Comparison of the BOPPPS model combined with rain classroom teaching and traditional method on nephrology education for fifth-year undergraduates. — Wang Y, Chen Z, Huang K, Zhang X, Chen C, Xu Y BMC medical education (2026)
[2]
Minimally invasive treatments for benign prostatic hyperplasia: A narrative review. — Zhang X, Liang T, Dong Y, Gao H Medicine (2026)
[3]
Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study. — Bevilacqua G, Carino D, Salciccia S, Gentilucci A, Forte F, Marco MD et al. The Prostate (2026)
[4]
Ejaculatory function after robotic waterjet ablation for the treatment of benign prostatic hyperplasia: a systematic review. — Bettencourt A, Wu J, Borrell JA, Furtado TP, Mills JN, Jayadevan R et al. International journal of impotence research (2026)
[5]
The Association Between Metabolic Syndrome and Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. — Gao W, Guo Y, Yu X, Zhang T, Gong H, Zhang Y American journal of men's health (2026)
[6]
Surgical Management of Benign Prostatic Hyperplasia: Analysis of Patient and Provider Factors Associated with Surgical Management Using the American Urological Association Quality Registry Dataset. — Edmonds V, Galen E, Mbassa R, Meeks W, Forbes CM, Bhojani N et al. Urology (2026)
[7]
Next-gen minimally invasive surgical therapies for benign prostatic hyperplasia: innovations, selection, and best practices- a review from European Association of Urology endourology. — Pace KJC, Li T, Elterman DS Current opinion in urology (2026)
[8]
How safe is teaching radical cystectomy? : Results from the prospective Swiss society of urology database. — Scherrer M, Brunaiova L, Furrer M, John H, Schwartz J, Lucca I et al. World journal of urology (2026)
[9]
Comparative analysis of EAU, AUA, and NCCN guidelines for the management of non-muscle invasive bladder cancer. — Aydın ME, Aykaç A, Kaya C, Sungur M BMC urology (2026)
[10]
Trends for ejaculatory sparing and minimally invasive surgical treatments adoption for lower urinary tract symptoms related to BPH in Italy: screenshot from the Italian society of urology (SIU) benign research network. — Mari A, Cindolo L, Fiori C, Lambertini L, Secco S, Russo GI et al. Minerva urology and nephrology (2026)
[11]
Guidelines adherence in non-muscle-invasive bladder cancer: a global survey of 3595 participants. — Abdulmajeed A, Bekiroglu F, Aydin A, Laguna P, Zeng G, Pavlov V et al. BJU international (2026)
[12]
Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group. — Saouli A, Contieri R, Quhal F, Hurle R, Guenouni M, Ploussard G et al. Actas urologicas espanolas (2026)
[13]
Implementation of problem-based learning pedagogy with integration of tamsulosin management in traditional urology residency training under the multidisciplinary team model. — Zhang C, Huang S, Jiang F, Pu X Pakistan journal of pharmaceutical sciences (2026)
[14]
Attendings versus supervised residents: Educational results and future perspective in transurethral resection of bladder tumors. — Diana P, Gallioli A, Uleri A, Mas L, Pujol R, Territo A et al. Actas urologicas espanolas (2026)
[15]
Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS). — Zhao Z, Wu C, Xiong Y, Wang W, Qin F, Yuan J The aging male : the official journal of the International Society for the Study of the Aging Male (2026)
[16]
Immune-Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis. — Gokhale P, Zapata LV Cancer medicine (2026)
[17]
Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data. — Lin J, Fu W, Huang J, Liu M, Cai H World journal of urology (2026)
[18]
Cardiovascular safety of 5α-reductase inhibitors in people with benign prostatic hyperplasia and type 2 diabetes: a propensity score-matched analysis. — Tu H, Ju C, McGurnaghan SJ, Blackbourn LAK, Pearson E, Wei L et al. European heart journal. Cardiovascular pharmacotherapy (2026)
[19]
A Rare Case of a Plasmacytoid and Sarcomatoid Differentiated Urothelial Bladder Carcinoma with a Single Metastasis to the Right Ventricle of the Heart and Rapid Review of Single Heart Metastasis in Bladder Cancer. — Münker KA, Reineke D, Schneidewind L, Müssgens C Urologia internationalis (2026)
[20]
Risk factors and management of hypotension and nausea during 5-aminolevulinic acid-assisted transurethral resection of bladder tumors under spinal anesthesia. — Hirao K, Sano T, Taniguchi H, Yanishi M, Muguruma K, Kinoshita H Photodiagnosis and photodynamic therapy (2026)
[21]
The Impact of Anesthesia-induced Intraoperative Hypotension on Hemostasis During Holmium Laser Enucleation of the Prostate. — Gunturi A, Ceraolo C, Kolady R, Dogra N, Cheng G, Hines L et al. Urology (2026)
[22]
Agent-specific differences in sustained intraoperative hypotension during oral 5-Aminolevulinic acid-guided transurethral resection of bladder tumor: A retrospective observational study. — Katsumata Y, Yamamoto S, Iwata H, Kuroiwa H, Fukuhara H, Fukata S et al. Photodiagnosis and photodynamic therapy (2026)
[23]
Bladder cancer-induced CVD mortality: Role of CAPG protein. — Shen J, Zhao Z, Li Z, Wang R PloS one (2026)
[24]
Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH). — Anract J, Klein C, Sarrazin C, Pinar U, Chevrot A, Fassi-Fehri H et al. The French journal of urology (2025)
[25]
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines. — van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Compérat E, Dimitropoulos K et al. European urology (2025)
[26]
Simulation-based training in minimally invasive surgical therapies (MIST): current evidence and future directions for artificial intelligence integration-a systematic review by EAU endourology. — Nedbal C, Gauhar V, Herrmann T, Singh A, Talyshinskii A, Al Jaafari F et al. World journal of urology (2025)
[27]
Is Pulse Modulation the Future of Laser Technology in Endourology: Evidence from a Literature Review - Section of EAU Endourology. — Corsini C, Robesti D, Villa L, Montorsi F, Pietropaolo A, Panthier F et al. European urology focus (2025)
[28]
Outcomes and safety of trans perineal laser ablation of the prostate: a systematic review. — Altieri VM, Di Bello F, Saldutto P, Rocca R, Romani ML, Vena W et al. World journal of urology (2025)
[29]
Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH. — Busetto GM, Lombardo R, De Nunzio C, Santoro G, Tocci E, Schiavone N et al. Prostate cancer and prostatic diseases (2025)
[30]
Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement. — Akgul B, Tozsin A, Aydın A, Tokas T, Romero-Otero J, Ortner G et al. World journal of urology (2025)
[31]
Randomized prospective trial comparing ejaculatory preservation HoLEP versus standard HoLEP: the other face of the coin. — Eliwa A, Aldarraji A, Abdelwahab K, Salem E World journal of urology (2025)
[32]
Five-year Follow-up of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods-A Noninferiority Randomised Controlled Trial of Urodynamics. — Clout M, Lewis AL, Cochrane M, Young GJ, Abrams P, Blair PS et al. European urology focus (2025)
[33]
Local anesthesia for UroLift — Moretto S, Wirtzfeld N, Doizi S World journal of urology (2025)
[34]
1470 nm diode laser enucleation versus bipolar transurethral resection of the prostate for the surgical management of benign prostatic hyperplasia: a randomized comparison. — Lin D, Luo C, Cui K, Xu H, Yuan H, Luan Y et al. Lasers in medical science (2025)
[35]
"Defining the Drip: A Systematic Review of Incontinence Definitions and Predictors Following HoLEP". — Ceraolo CA, Winzer BM, Fairbourn JD, Phan D, Jain RK, Quarrier SO Current urology reports (2025)
[36]
Effects of alpha-1 adrenergic receptor blockers on erectile function: a systematic review. — Bakr AM, El-Sakka AI Expert opinion on pharmacotherapy (2025)
[37]
Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. — Copelan O, Moss J, Freedman S, Coutinho K, Elterman D, Marotte J et al. The journal of sexual medicine (2025)
[38]
Comparative study of low-power versus high-power holmium laser enucleation of the prostate for large volume benign prostatic hyperplasia. — Du R, Wang P, Gao Z, Liu H, Sun Z, Gu L et al. Lasers in medical science (2025)
[39]
Current Guidelines for the Management of Benign Prostatic Obstruction: Practical Tips for Patient Selection to Achieve Optimal Outcomes. — Baboudjian M, De Nunzio C, Cornu JN European urology focus (2025)
[40]
Randomised controlled trial comparing safety and efficacy of Urolift to monopolar TURP. — Sheba M, El Gamal F, Abd El Wahed M, Kotb S, Meshref A, Aly Hussein H et al. Urologia (2025)
[41]
Transurethral resection of the prostate across continents: a meta-analysis evaluating quality of gold standard in the twenty-first century. — Porto JG, Bhatia AM, Bhat A, Suarez Arbelaez MC, Blachman-Braun R, Shah K et al. World journal of urology (2025)
[42]
Complication rate across the minimally invasive surgical treatments (MISTs): where do we stand? A systematic review of the literature. — Lambertini L, Sandulli A, Coco S, Paganelli D, Cadenar A, Dell'Oglio P et al. Prostate cancer and prostatic diseases (2025)
[43]
Practical Approaches to Evaluating Patients with Benign Prostatic Hyperlasia Using Home-based Tools and Apps. — Schwartzmann I, Chughtai B European urology focus (2025)
[44]
Paradigm shift in the treatment of bladder cancer? The Swedish perspective. — Malmström PU, Wang EYH Scandinavian journal of urology (2025)
[45]
A Urologist's Guide to Managing Bladder Cancer in Patients Who Smoke. — Wong R, Matulewicz RS, Bjurlin MA European urology focus (2025)
[46]
Do We Need Referral Centers for Benign Prostatic Hyperplasia that Offer More Options with Expertise? Con. — Uleri A, Fourmarier M, Long-Depaquit T, Baboudjian M European urology focus (2025)
[47]
Vibe Coding in nephrology education: clinician-led, AI-assisted development of open-source interactive learning tools. — Pesce F, Cheungpasitporn W Renal failure (2025)
[48]
Roadmap for the transition to robotic radial cystectomy for patients with bladder cancer in a tertiary urology unit: planning for change. — Keenan RA BMJ leader (2025)
[49]
Student Urology Conference Increases Participant Knowledge of Urology Match and Confidence in Research. — Kim IE, Allu S, Whittelsey M, Kent V, Onal EG, Nguyen C et al. Urology (2025)
[50]
Bridging Perspectives: Integrating urologist and cytopathologist insights of urine cytology. — Khorsandi N, Porten S, VandenBussche CJ, Greenland N, Vohra P Seminars in diagnostic pathology (2025)
[51]
Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy. — Farré A, Huguet J, Basile G, Diéguez L, Izquierdo P, Sánchez R et al. Actas urologicas espanolas (2025)
[52]
Clinical Implementation of Urinary Biomarkers for Surveillance of Non-muscle-invasive Bladder Cancer (NMIBC): Considerations from the European Association of Urology NMIBC Guideline Panel. — Liedberg F, Mariappan P, Gontero P European urology oncology (2025)
[53]
Chatgpt vs traditional pedagogy: a comparative study in urological learning. — Digiacomo A, Orsini A, Cicchetti R, Spadano L, De Santis S, Di Sessa L et al. World journal of urology (2025)
[54]
Benign Prostatic Hyperplasia Knowledge Deficits Among Male Urology Patients. — Ramanujan S, Orji P, Chiu A, Kumar SS, Jevnikar W, Cox B et al. Urology (2025)
[55]
Beyond Citations: Exploring Gender and Racial Gaps in Urology Publications Through Citation and Altmetric Analysis. — Wang B, Nandwana D, Helstrom E, Davis LE, Mishra K, Campbell R et al. Urology (2025)
[56]
Improving the quality of transurethral resection of bladder tumour (TURBT) operative notes following the European Association of Urology guidelines. — Ryan PC, Sugrue DD, O'Connell C, Salloum A, Lynch TH, Smyth L et al. Irish journal of medical science (2025)
[57]
Real-life perception of pathology reports in urology. — Cimadamore A, Moschini M, Teoh J, Albisinni S, Adwin Z, Shen Ta W et al. Actas urologicas espanolas (2025)
[58]
Current utility of artificial intelligence in benign prostate surgery: a review of literature on behalf of the EAU section of endourology. — Nedbal C, Tramanzoli P, Somani BK, De Stefano V, Stramucci S, Pirola GM et al. World journal of urology (2025)
[59]
The current role of photodynamic diagnosis (PDD) in the management of non-muscle invasive bladder cancer: the Italian Society of Urology (SIU) Position Paper. — Soria F, Mari A, Moschini M, Naspro R, Hurle R, Miglioranza E et al. Minerva urology and nephrology (2025)
[60]
Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels. — Mertens LS, Bruins HM, Contieri R, Babjuk M, Rai BP, Puig AC et al. European urology oncology (2025)
[61]
The worldwide adoption of enhanced endoscopic imaging in diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC): snapshot analysis from a global survey. — Bekiroglu F, Abdulmajeed A, Aydin A, Laguna P, Zeng G, Pavlov V et al. World journal of urology (2025)
[62]
Educating the Educator: Understanding Essential Components of Contemporary Urology Residency Training. — Yong C Current urology reports (2025)
[63]
Comparing the clinical outcomes and learning curves of prostatic urethral lift performed by experienced versus naïve urologists. — Hsieh TY, Hong JH, Chueh JS World journal of urology (2025)
[64]
The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer. — Abou Chakra M, Packiam VT, McElree IM, Mott SL, O'Donnell MA Urologic oncology (2025)
[65]
New Paradigms for Bladder Cancer Management in Geriatrics. — MacDonald L, Smith M, Bree KK Clinics in geriatric medicine (2025)
[66]
Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database. — Wang B, Bao EH, Jiang BL, Yang L, Liu Y, Xia L et al. Expert opinion on drug safety (2025)
[67]
Real-world safety assessment of tamsulosin based on adverse event analysis from the FAERS database. — Zhang Z, Lv L, Jiang F, Guan S, He D, Song H et al. Scientific reports (2025)
[68]
Finasteride Use: Evaluation of Depression and Suicide Risk. — Gupta AK, Bamimore MA, Williams G, Talukder M Journal of cosmetic dermatology (2025)
[69]
Reassessment of pioglitazone and bladder cancer based on FAERS database. — Chen HY, Zhao H, Yang JJ, Zhang Q, Yan MM, Qiu XY Expert opinion on drug safety (2025)
[70]
Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system. — Liu X, Wang Z, Peng C, Zhou J, Chen M, Luo L et al. Expert opinion on drug safety (2025)
[71]
Whole Genome Sequencing of Clinical — Nakagawa Y, Yamamoto C, Kawajiri H, Watanabe M, Yamada T, Yamada Y et al. International journal of molecular sciences (2025)
[72]
Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes. — Ahmed ME, Andrews JR, Mahmoud AM, Reitano G, Thapa P, Tyson MD et al. The Journal of urology (2025)
[73]
Transurethral resection of the prostate (TUR-P) and associated risk of infective endocarditis. — Fosbøl EL, Stahl A, Røder A, Nordsten CB, Østergaard L, Sehested TSG et al. Infection (2025)
[74]
Multiple arterial aneurysms in a patient with spondylitis following intravesical Bacillus Calmette-Guérin administration for bladder cancer: A case report. — Yonezaki S, Shimizu MS, Ota T, Ozasa S, Akabame S, Ide S et al. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2025)
[75]
Comparison of direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for venous thromboprophylaxis after radical cystectomy: A systematic review and meta-analysis. — Tania C, Sihombing AT, Siregar S Urologic oncology (2025)
[76]
The association between alphablockers in the treatment of benign prostatic hyperplasia and heart failure: A nationwide population-based cohort study in South Korea. — Jeong JY, Kim MK, Shin JY International journal of clinical pharmacology and therapeutics (2025)
[77]
[Minimally invasive treatment of benign prostatic hyperplasia : The German S2e guideline 2023-part 4]. — Salem J, Becher KF, Bschleipfer T, Dreikorn K, Höfner K, Madersbacher S et al. Urologie (Heidelberg, Germany) (2024)
[78]
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. — Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC et al. The Journal of urology (2024)
[79]
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. — Gontero P, Birtle A, Capoun O, Compérat E, Dominguez-Escrig JL, Liedberg F et al. European urology (2024)
[80]
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). — Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC et al. The Journal of urology (2024)
[81]
The Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults Presenting with Haematuria: A Systematic Review from the European Association of Urology Guidelines Office. — Devlies W, de Jong JJ, Hofmann F, Bruins HM, Zuiverloon TCM, Smith EJ et al. European urology focus (2024)
[82]
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. — Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK et al. Journal of the National Comprehensive Cancer Network : JNCCN (2024)
[83]
Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. — Yoosuf BT, Panda AK, Kt MF, Bharti SK, Devana SK, Bansal D Scientific reports (2024)
[84]
Association between metabolic syndrome and benign prostatic hyperplasia: The underlying molecular connection. — Fu X, Wang Y, Lu Y, Liu J, Li H Life sciences (2024)
[85]
Evaluating transurethral resection of the prostate over twenty years: a systematic review and meta-analysis of randomized clinical trials. — Porto JG, Bhatia AM, Bhat A, Suarez Arbelaez MC, Blachman-Braun R, Shah K et al. World journal of urology (2024)
[86]
Systematic review and network meta-analysis of re-intervention rates of new surgical interventions for benign prostatic hyperplasia. — Shin BNH, Qu L, Rhee H, Chung E BJU international (2024)
[87]
The safety and efficacy of five surgical treatments in prostate enucleation: a network meta-analysis. — Chen YY, Hua WX, Huang YH, Shen XY, You JN, Ding X BMC urology (2024)
[88]
Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes. — Tawfik A, Abo-Elenen M, Gaber M, El-Abd A, Zoeir A, Saad S et al. World journal of urology (2024)
[89]
The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder. — Hagovska M, Svihra J, Macko L, Breza J, Svihra J, Luptak J et al. World journal of urology (2024)
[90]
Two-year follow-up comparing Rezūm therapy versus bipolar transurethral resection of the prostate for treating benign prostatic hyperplasia. A prospective randomized study. — Samir M, Elaal AAA, Gad KAS, Basyony MW International journal of urology : official journal of the Japanese Urological Association (2024)
[91]
Enhancing continence post holmium laser enucleation of the prostate: assessment of novel technique through randomized clinical trial. — Elshal AM, Ghazy M, Ghobrial FK Minerva urology and nephrology (2024)
[92]
A systematic review of robot-assisted simple prostatectomy outcomes by prostate volume. — Morozov A, Bogatova S, Bezrukov E, Singla N, Teoh JY, Spivak L et al. World journal of urology (2024)
[93]
Open simple prostatectomy in the last three decades: results of a meta-analysis. — Titus RS, Bhatia A, Porto JG, Shah K, Lopategui DM, Herrmann TRW et al. World journal of urology (2024)
[94]
Transurethral surgical treatment for benign prostatic hyperplasia with detrusor underactivity: a systematic review and meta-analysis. — Zou P, Liu C, Zhang Y, Wei C, Liu X, Xu S et al. Systematic reviews (2024)
[95]
Minimally invasive connective water vapor energy method for benign prostatic hyperplasia. — Çakıroğlu B Urologia (2024)
[96]
Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan's public healthcare system. — Anezaki H, Endo F, Swan G, Takashima K, Rojanasarot S Journal of medical economics (2024)
[97]
Salvage holmium laser enucleation of the prostate after previous interventions: a systematic review. — Kallidonis P, Spinos T, Peteinaris A, Somani B, Liatsikos E BJU international (2024)
[98]
Tranexamic acid for reducing blood loss in bipolar transurethral resection of the prostate: a systematic review of literature. — Cha JD, Galindo GFC, Denser CV, Silva CHAD, Carneiro A Einstein (Sao Paulo, Brazil) (2024)
[99]
Association of 5α-Reductase Inhibitors with Depression and Suicide: A Mini Systematic Review and Meta-analysis. — Uleri A, Nicolas Cornu J, Gobbo A, Herrmann TRW, De Nunzio C, Hashim H et al. European urology focus (2024)
[100]
Embracing the (r)evolution of social media and digital scholarship in pediatric nephrology education. — Shah SS, Zangla E, Qader MA, Chaturvedi S, Mannemuddhu SS Pediatric nephrology (Berlin, Germany) (2024)

Share:Twitter Reddit LinkedIn